MX344163B - Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas. - Google Patents
Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas.Info
- Publication number
- MX344163B MX344163B MX2012008301A MX2012008301A MX344163B MX 344163 B MX344163 B MX 344163B MX 2012008301 A MX2012008301 A MX 2012008301A MX 2012008301 A MX2012008301 A MX 2012008301A MX 344163 B MX344163 B MX 344163B
- Authority
- MX
- Mexico
- Prior art keywords
- loratadine
- formulation
- encapsulation
- combinations
- dosage unit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención se relaciona a una formulación de loratadina adecuada para la encapsulación en una cápsula de gel blando o unidad de dosificación adecuada con funcionalidad mejorada que proporciona disolución y biodisponibilidad in vitro aumentada de loratadina. La invención también proporciona una formulación con funcionalidad mejorada como una solución altamente concentrada dentro de un volumen de llenado dado con el fin de fabricar una cápsula tan pequeña como sea posible para facilitar la aceptación del consumidor y costos de fabricación aceptables. La invención también se relaciona a una formulación de estabilidad óptima adecuada para soportar una composición de llenado compatible con la unidad de dosificación de cápsula de gel blando.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2690490A CA2690490C (en) | 2010-01-19 | 2010-01-19 | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
| PCT/CA2011/000052 WO2011088550A1 (en) | 2010-01-19 | 2011-01-18 | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012008301A MX2012008301A (es) | 2012-09-28 |
| MX344163B true MX344163B (es) | 2016-12-07 |
Family
ID=44303619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012008301A MX344163B (es) | 2010-01-19 | 2011-01-18 | Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20120301544A1 (es) |
| EP (2) | EP3653204A1 (es) |
| JP (1) | JP5328992B2 (es) |
| AU (1) | AU2011207058B2 (es) |
| CA (1) | CA2690490C (es) |
| CY (1) | CY1123895T1 (es) |
| DK (1) | DK2525827T3 (es) |
| ES (1) | ES2843351T3 (es) |
| HR (1) | HRP20201923T1 (es) |
| HU (1) | HUE053412T2 (es) |
| LT (1) | LT2525827T (es) |
| MX (1) | MX344163B (es) |
| PL (1) | PL2525827T3 (es) |
| PT (1) | PT2525827T (es) |
| RS (1) | RS61362B1 (es) |
| SI (1) | SI2525827T1 (es) |
| WO (1) | WO2011088550A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784446B (zh) * | 2014-03-05 | 2016-01-06 | 大连金石滩药业有限公司 | 氯雷他定组合物 |
| CN103784399B (zh) * | 2014-03-05 | 2015-09-30 | 大连金石滩药业有限公司 | 氯雷他定液体组合物 |
| JP7065562B2 (ja) * | 2015-09-04 | 2022-05-12 | ロート製薬株式会社 | 医薬組成物 |
| KR101746500B1 (ko) | 2016-05-26 | 2017-06-14 | (주)알피바이오 | 연질캡슐 제제용 로라타딘 조성물 및 이를 함유하는 연질캡슐 |
| WO2019113461A1 (en) | 2017-12-08 | 2019-06-13 | Western University Of Health Sciences | Lipid emulsified drug delivery systems for chemoprevention and treatment |
| MX2020012233A (es) | 2018-05-16 | 2021-01-29 | Bayer Healthcare Llc | Formula de suspension de alta concentracion para medicamentos en capsula de gel blanda para resfriado y gripe. |
| CN112426404B (zh) * | 2020-10-29 | 2023-02-28 | 太阳升(亳州)生物医药科技有限公司 | 用于制备富马酸卢帕他定口服液的方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282233B1 (en) | 1980-06-19 | 2000-09-05 | Schering Corp | Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines |
| AU570306B2 (en) | 1984-02-15 | 1988-03-10 | Schering Corporation | 8-chloro-6, 11-dihydro-11-(4-piperidylidene)-5h-benzo (5,6) cyclohepta (1,2-b) pyridine and its salts. |
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US4910205A (en) | 1988-05-02 | 1990-03-20 | Schering Corporation | Transdermal delivery of loratadine |
| US4863931A (en) | 1988-09-15 | 1989-09-05 | Schering Corporation | Antihistaminic fluoro substituted benzocycloheptapyridines |
| US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| AU667316B2 (en) * | 1991-07-26 | 1996-03-21 | Smithkline Beecham Corporation | W/O microemulsions |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| GB9226238D0 (en) | 1992-12-16 | 1993-02-10 | Scherer Ltd R P | Encapsulation apparatus and process |
| US6054136A (en) * | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| CA2181241C (en) * | 1994-01-24 | 2000-04-25 | Dadi Jamshed Dhabhar | Process for solubilizing difficultly soluble pharmaceutical actives |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| DE69525740T2 (de) * | 1994-04-07 | 2002-10-24 | Smithkline Beecham Plc | Spezielle halofantrinhaltige Zusammensetzungen |
| US5595997A (en) | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| WO1999036060A1 (en) * | 1998-01-20 | 1999-07-22 | Applied Analytical Industries, Inc. | Oral liquid compositions |
| US6132758A (en) | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| ES2226289T3 (es) | 1998-06-30 | 2005-03-16 | Pfizer Products Inc. | Loratadina para uso como antiarritmico. |
| US6221391B1 (en) * | 1998-11-23 | 2001-04-24 | Accucaps Industries Limited | Self-emulsifying ibuprofen solution and soft gelatin capsule for use therewith |
| US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| US6720002B2 (en) * | 2001-07-20 | 2004-04-13 | R.P. Scherer Technologies, Inc. | Antihistamine formulations for soft capsule dosage forms |
| CA2466868C (en) * | 2001-12-21 | 2010-06-22 | Shire Laboratories Inc. | Oral capsule formulation with increased physical stability |
| US20040033257A1 (en) * | 2002-05-30 | 2004-02-19 | Strides Inc. | Pharmaceutical formulation in a drug delivery system and process for preparing the same |
| KR100533460B1 (ko) * | 2002-07-20 | 2005-12-08 | 대화제약 주식회사 | 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법 |
| WO2006104703A1 (en) * | 2005-03-29 | 2006-10-05 | Mcneil-Ppc, Inc. | Compositions with hydrophilic drugs in a hydrophobic medium |
| US20110020440A1 (en) * | 2007-11-19 | 2011-01-27 | Cadila Pharmaceuticals Limited | Stable solutions of sparingly soluble actives |
-
2010
- 2010-01-19 CA CA2690490A patent/CA2690490C/en active Active
-
2011
- 2011-01-18 RS RS20210013A patent/RS61362B1/sr unknown
- 2011-01-18 DK DK11734280.8T patent/DK2525827T3/da active
- 2011-01-18 MX MX2012008301A patent/MX344163B/es active IP Right Grant
- 2011-01-18 EP EP19217776.4A patent/EP3653204A1/en active Pending
- 2011-01-18 LT LTEP11734280.8T patent/LT2525827T/lt unknown
- 2011-01-18 JP JP2012549213A patent/JP5328992B2/ja not_active Expired - Fee Related
- 2011-01-18 US US13/574,189 patent/US20120301544A1/en active Pending
- 2011-01-18 AU AU2011207058A patent/AU2011207058B2/en active Active
- 2011-01-18 SI SI201131943T patent/SI2525827T1/sl unknown
- 2011-01-18 EP EP11734280.8A patent/EP2525827B1/en active Active
- 2011-01-18 PT PT117342808T patent/PT2525827T/pt unknown
- 2011-01-18 WO PCT/CA2011/000052 patent/WO2011088550A1/en active Application Filing
- 2011-01-18 HU HUE11734280A patent/HUE053412T2/hu unknown
- 2011-01-18 ES ES11734280T patent/ES2843351T3/es active Active
- 2011-01-18 PL PL11734280T patent/PL2525827T3/pl unknown
-
2020
- 2020-12-02 HR HRP20201923TT patent/HRP20201923T1/hr unknown
-
2021
- 2021-01-13 CY CY20211100020T patent/CY1123895T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2525827T3 (pl) | 2021-05-04 |
| LT2525827T (lt) | 2021-03-25 |
| ES2843351T3 (es) | 2021-07-16 |
| HUE053412T2 (hu) | 2021-06-28 |
| DK2525827T3 (da) | 2020-12-14 |
| WO2011088550A1 (en) | 2011-07-28 |
| HRP20201923T1 (hr) | 2021-02-05 |
| EP2525827A4 (en) | 2014-04-30 |
| MX2012008301A (es) | 2012-09-28 |
| CY1123895T1 (el) | 2022-05-27 |
| JP2013517303A (ja) | 2013-05-16 |
| EP2525827B1 (en) | 2020-11-18 |
| RS61362B1 (sr) | 2021-02-26 |
| SI2525827T1 (sl) | 2021-02-26 |
| JP5328992B2 (ja) | 2013-10-30 |
| CA2690490A1 (en) | 2011-07-19 |
| CA2690490C (en) | 2012-06-26 |
| AU2011207058B2 (en) | 2015-04-23 |
| PT2525827T (pt) | 2021-01-20 |
| AU2011207058A1 (en) | 2012-09-06 |
| EP3653204A1 (en) | 2020-05-20 |
| US20120301544A1 (en) | 2012-11-29 |
| EP2525827A1 (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX344163B (es) | Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas. | |
| IL244945B (en) | Cationic lipid, lipid formulations including it and their use in the preparation of therapeutic agents for administration to cells | |
| TN2010000152A1 (en) | Pharmaceutical compositions | |
| HK1182010A1 (en) | Liquid pharmaceutical composition for the delivery of active ingredients | |
| WO2011093823A3 (en) | Effervescent formulations comprising cefaclor and clavulanic acid | |
| IL208832A (en) | 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation | |
| IL218071A0 (en) | Novel pharmaceutical formulations to prevent the misuse of medicinal drugs | |
| WO2011146876A3 (en) | Oral transmucosal administration of sufentanil | |
| IL220465A0 (en) | Methods and compositions for stable liquid drug formulations | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| IL222578A0 (en) | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same | |
| MX358636B (es) | Formulaciones farmacéuticas de naproxeno para la encapsulación en gel blando y combinaciones de las mismas. | |
| MX2012002831A (es) | Formulaciones para suspension oral de acetato de esclicarbazepina. | |
| EP2150235A4 (en) | Capsule formulation coated with nanoparticles for the purpose of dermal drug administration | |
| PT2568970T (pt) | Formulações farmacêuticas estáveis contendo um anti-histamínico | |
| WO2011095801A3 (en) | Liquid pharmaceutical composition for buccal administration comprising morphine | |
| ZA201500411B (en) | Formulations for the preparation of immediate-release tablets for oral administration containing low-dose mifepristone, tablets thus obtained and their preparation process | |
| EP2529755A4 (en) | PHARMACEUTICAL COMPOSITION AND PREPARATION THEREFOR FOR ORAL ADMINISTRATION | |
| GB201008049D0 (en) | Composition | |
| TW200833375A (en) | Pharmaceutical compositions | |
| GB201005204D0 (en) | Improvements in heterotypic formulations of anticancer drugs | |
| EP2436383A4 (en) | ORAL ACETIC COMPOSITION AND ORAL CAPSULE WITH THE INGREDIENTS COMPRISED THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |